This Article Full Text Full Text (PDF) Supplemental Data Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tabruyn, S. P. Articles by Struman, I. Search for Related Content PubMed PubMed Citation Articles by Tabruyn, S. P. Articles by Struman, I.

The Angiostatic 16K Human Prolactin Overcomes Endothelial Cell Anergy and Promotes Leukocyte Infiltration via Nuclear Factor-B Activation

Unit of Molecular Biology and Genetic Engineering (S.P.T., C.S., N.-Q.-N.N., L.M., J.A.M., I.S.) and Unit of Medical Chemistry and Human Genetics (C.V.), GIGA Research, University of Liege, 4000 Liege, Belgium; and Angiogenesis Laboratory (S.P.T., K.C., A.W.G.), Department of Pathology, Research Institute For Growth and Development (GROW), Maastricht University and University Hospital, 6202 AZ Maastricht, The Netherlands

Address all correspondence and requests for reprints to: Joseph Martial, Ph.D., Unit of Molecular Biology and Genetic Engineering. GIGA Research, GIGA, B34, 1 Avenue de l’Hopital, University of Liege, Sart Tilman 4000, Belgium. E-mail: jmartial{at}ulg.ac.be.

The 16-kDa N-terminal fragment of human prolactin (16K hPRL) is a potent angiostatic factor that inhibits tumor growth in mouse models. Using microarray experiments, we have dissected how the endothelial-cell genome responds to 16K hPRL treatment. We found 216 genes that show regulation by 16K hPRL, of which a large proportion turned out to be associated with the process of immunity. 16K hPRL induces expression of various chemokines and endothelial adhesion molecules. These expressions, under the control of nuclear factor-B, result in an enhanced leukocyte-endothelial cell interaction. Furthermore, analysis of B16-F10 tumor tissues reveals a higher expression of adhesion molecules (intercellular adhesion molecule 1, vascular cell adhesion molecule 1, or E-selectin) in endothelial cells and a significantly higher number of infiltrated leukocytes within the tumor treated with 16K hPRL compared with the untreated ones. In conclusion, this study describes a new antitumor mechanism of 16K hPRL. Because cellular immunity against tumor cells is a crucial step in therapy, the discovery that treatment with 16K hPRL overcomes tumor-induced anergy may become important for therapeutic perspectives.

This article has been cited by other articles:

				C. Clapp, S. Thebault, M. C. Jeziorski, and G. Martinez De La Escalera Peptide Hormone Regulation of Angiogenesis Physiol Rev, October 1, 2009; 89(4): 1177 - 1215. [Abstract] [Full Text] [PDF]

				S. P. Tabruyn, S. Memet, P. Ave, C. Verhaeghe, K. H. Mayo, I. Struman, J. A. Martial, and A. W. Griffioen NF-{kappa}B activation in endothelial cells is critical for the activity of angiostatic agents Mol. Cancer Ther., September 1, 2009; 8(9): 2645 - 2654. [Abstract] [Full Text] [PDF]

				C. Clapp, S. Thebault, E. Arnold, C. Garcia, J. C. Rivera, and G. M. de la Escalera Vasoinhibins: novel inhibitors of ocular angiogenesis Am J Physiol Endocrinol Metab, October 1, 2008; 295(4): E772 - E778. [Abstract] [Full Text] [PDF]

				O. Forster, D. Hilfiker-Kleiner, A. A. Ansari, J. B. Sundstrom, E. Libhaber, W. Tshani, A. Becker, A. Yip, G. Klein, and K. Sliwa Reversal of IFN-{gamma}, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy Eur J Heart Fail, September 1, 2008; 10(9): 861 - 868. [Abstract] [Full Text] [PDF]